Ajanta Pharma Performance
- Today's Low
- ₹3,182
- Today's High
- ₹3,258
- 52 Week Low
- ₹2,330
- 52 Week High
- ₹3,315
- Open Price₹3,250
- Previous Close₹3,248
- Volume47,927
- 50 DMA₹2,957.02
- 100 DMA₹2,875.58
- 200 DMA₹2,787.42
Ajanta Pharma Chart
Investment Returns
- Over 1 Month + 13.23%
- Over 3 Month + 7.14%
- Over 6 Month + 25.43%
- Over 1 Year + 21.17%
Smart Investing Starts Here Start SIP with Ajanta Pharma for Steady Growth!
Ajanta Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 37.3
- PEG Ratio
- 2.5
- Market Cap Cr
- 39,337
- P/B Ratio
- 8.6
- Average True Range
- 95.49
- EPS
- 84.52
- Dividend Yield
- 0.9
- MACD Signal
- 78.59
- RSI
- 59.94
- MFI
- 75.8
Latest Stock News Updates
Ajanta Pharma Ltd on Tuesday reported a 18.4 per cent rise in consolidated net profit at Rs 266.7 crore in the fourth quarter ended March 31, on the back of strong US generics revenue growth. The company had posted a consolidated net profit of Rs 225.26 crore in the corresponding period previous fiscal, Ajanta Pharma Ltd said in a regulatory filing. Consolidated revenue from operations in the fourth quarter stood at Rs 1,421.64 crore as against Rs 1,170.41 crore in the year-ago period, it added. During the quarter branded generics in the markets of India, Asia and Africa clocked a combined revenue of Rs 859 crore as compared to Rs 805 crore in the year-ago period, up 7 per cent. US generic revenue was at Rs 505 crore as compared to Rs 325 crore in the same period a year ago, up 56 per cent, the company said. Total expenses in the fourth quarter were higher at Rs 1,135.96 crore as compared to Rs 919.11 crore in the same period a year ago, the company said. For FY26, consolidated n
- Business Standard
- 2 weeks 2 days ago
Conference Call with Ajanta Pharma Management and Analysts on Q4FY26 & Full Year Performance and Outlook. Listen to the full earnings transcript.
- Trendlyne
- 2 weeks 2 days ago
Pharmaceuticals company Ajanta Pharma announced Q4FY26 & FY26 results Q4FY26 Financial Highlights: Revenue from operations at Rs 1,422 crore against Rs 1,170 crore; up 21%. EBITDA at Rs 333 crore against Rs 297 crore; EBITDA at 23%; up 12%. The mark-to-market forex loss stood at Rs 42 crore Excluding this impact, EBITDA stood at Rs 375 crore, reflecting a 26% growth, with an EBITDA margin of 26%. Profit after tax at Rs 267 crore against Rs 225 crore; PAT at 19%; up 18%. FY26 Financial Highlights: Revenue from operations at Rs 5,453 crore against Rs 4,648 crore; up 17%. EBITDA at Rs 1,395 crore against Rs 1,260 crore; EBITDA at 26%; up 11%. The mark-to-market forex loss stood at Rs 103 crore Excluding this impact, EBITDA stood at Rs 1,498 crore, reflecting a 18% growth, with an EBITDA margin of 27%. Profit after tax at Rs 1,056 crore against Rs 920 crore; PAT at 19%; up 15%. ROCE stood at a healthy level of 33% and RONW at 25%. Result PDF
- Trendlyne
- 2 weeks 2 days ago
Ajanta Pharma Financials
Ajanta Pharma Technicals
EMA & SMA
- Bearish Moving Average 3
- Bullish Moving Average 13
- 20 Day
- ₹3,059.60
- 50 Day
- ₹2,957.02
- 100 Day
- ₹2,875.58
- 200 Day
- ₹2,787.42
Resistance and Support
- R3 3,279.33
- R2 3,249.67
- R1 3,199.43
- S1 3,119.53
- S2 3,089.87
- S3 3,039.63
Ajanta Pharma Corporate Actions - Bonus, Splits, Dividends
About Ajanta Pharma
- NSE Symbol
- AJANTPHARM
- BSE Symbol
- 532331
- Managing Director
- Mr. Yogesh M Agrawal
- ISIN
- INE031B01049
Similar Stocks to Ajanta Pharma
Popular Stocks
Ajanta Pharma FAQs
Ajanta Pharma share price is ₹3,149 As on 21 May, 2026 | 21:52
The Market Cap of Ajanta Pharma is ₹39337.3 Cr As on 21 May, 2026 | 21:52
The P/E ratio of Ajanta Pharma is 37.3 As on 21 May, 2026 | 21:52
The PB ratio of Ajanta Pharma is 8.6 As on 21 May, 2026 | 21:52
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.